Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable ...

LONDON — The lucky number is 7 — or 7.1 to be exact — the mean optimum number of injections of intravitreal ranibizumab (Lucentis, Genentech) that should be given during the first year of treatment ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluating ...

VANCOUVER, British Columbia — While eye pain outcomes were similar within a week of injection of either aflibercept or ranibizumab in patients with diabetic macular edema, more anterior chamber ...

<0> GenentechMedia Contact:Terence Hurley, 650-467-6800orInvestor Relations:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 8503 </0> Genentech, a member of the Roche Group (SIX: RO, ROG; ...

The ranibizumab ocular implant (Susvimo) reduces the need for frequent intravitreal anti-VEGF injections in patients with neovascular age-related macular degeneration or diabetic macular edema, and ...

Ranibizumab, an anti-vascular endothelial growth factor, and dexamethasone, a corticosteroid, have been shown to be effective in treating macular oedema secondary to retinal vein occlusion (RVO) ...

Bevacizumab (Avastin, Genentech) injections do not raise the risk for endophthalmitis compared with injections of its manufacturer's more costly counterpart, ranibizumab (Lucentis), according to a ...

Archway (NCT03677934) is a randomized, multicenter, open-label Phase III study evaluating the efficacy and safety of Port Delivery System with ranibizumab (PDS), refilled every six months at fixed ...